Slide 1: Nexstim - Personalized Brain Diagnostics and Therapy
Nexstim - Personalized Brain Diagnostics and Therapy Mikko Karvinen| CEO| Nexstim Plc Joonas Juokslahti| CFO| Nexstim Plc H2 2024 & FY 2024 Financial Results Webinar, 27 February 2025
Slide 2: Nexstim Oyj
System and service sales volume increase through a successful Brainlab Continued development of competitive partnership bridging neuro- system and service offering in approved surgery, neurophysiology indications (Depression & Chronic Pain). and neuroscience. Expansion into possible new indications
Slide 3: Nexstim Plc Public Presentation
Nexstim Plc Public Presentation 3
Slide 4: Nexstim and Brainlab have started a collaboration
Nexstim and Brainlab have started a collaboration by signing a development and distributorship cooperation agreement. Nexstim has created a world-leading non- invasive brain mapping technology based on navigated transcranial magnetic stimulation. Together, the two companies will develop new solution
Slide 5: Non-invasive brain motor mapping in 20 minutes
Non-invasive brain motor mapping in 20 minutes 1 Prepare Upload the 2 Register Register the 3 Stimulate 3D mapping of 4 Evaluate Review areas eliciting 5 Export Bring data into MRI image patient head to the brain responses to avoid surgical planning their MRI during surgery and navigation tools Nexs
Slide 6: Our Business and Products
Our Business and Products Commercial Business System Application Europe United States Status NBS 5 Diagnostics (Navigated Over 240 Pre-surgical FDA CE marked Business Brain systems sold mapping approved Stimulation) FDA approved NBT® & NBS 6 Over 100 Depression CE marked with existing Therapy (Navig
Slide 7: Business and Financial Summary H2 2024
Nexstim Business and Financial Summary H2 2024 • Nexstim continued profitable growth and signed • System sales were EUR 3.6M (2023 H2: EUR 3.0M), significant partnerships with an increase of 19.5%. Recurring net sales were • In line with our main strategic objective, we have continued EUR 2.0M (2023
Slide 8: Financial Development H2 2020-2024 (k€)
Nexstim Financial Development H2 2020-2024 (k€) Comparable net sales Comparable gross margin EBITDA EBIT 6 000 5 000 4 000 3 000 EUR 1000 2 000 1 000 0 H2 20 H2 21 H2 22 H2 23 H2 24 -1 000 -2 000 Nexstim Oyj Nexstim Plc Public Presentation 8
Slide 9: Group Key Financials H2 & Full Year 2024
Nexstim Group Key Financials H2 & Full Year 2024 7–12/2024 7–12/2023 1–12/2024 1–12/2023 • Comparable 8.7M€ +21 % EUR in thousands Change-% Change-% 6 months 6 months 12 months 12 months • System sales 4.8M€ +17 % • Recurring 3.9M€ +25 % Net Sales 5,559 4,743 17.2 % 8,735 7,246 20.5 % • Diagnostic 4
Slide 10: Comparable Net Sales and Gross Margin 2020-2024
Comparable Net Sales and Gross Margin 2020-2024 Comparable net sales Comparable gross margin 10 000 9 000 8 000 7 000 6 000 EUR 1000 5 000 4 000 3 000 2 000 1 000 0 FY 20 FY 21 FY 22 FY 23 FY 24 Nexstim Oyj Nexstim Plc Public Presentation 10
Slide 11: Key Strategic Objectives 2025
Nexstim Key Strategic Objectives 2025 1 2 3 Profitable Growth Strategic Partnerships Technology leadership Increase net sales and Successfully supporting Launching the new NBS 6 improve operating result the long-term diagnostics system in key for the financial year collaboration between markets, ena
Slide 12: NBS 6 – future of the Nexstim system
NBS 6 – future of the Nexstim system Commercialization of the new product generation is an essential part of Nexstim’s 2025-2028 strategy period • The NBS 6 is a new combined system that has been built on Nexstim’s unique, clinically established technology. • The modular product design allows for an
Slide 13: Thank you!
Thank you! @NexstimOyj Follow us on social media: @Nexstim @NexstimTMS Nexstim Oyj Nexstim Plc Public Presentation 13
Slide 14: Important Information
Important Information This document and the information contained herein are being presented by Nexstim Oyj as, a promise or representation as to future performance. The Company does not undertake any (“Nexstim” or the “Company”). In connection with any presentation or review of this document, oblig